[go: up one dir, main page]

HK1091403A1 - 5-ht 1a receptor subtype agonist - Google Patents

5-ht 1a receptor subtype agonist

Info

Publication number
HK1091403A1
HK1091403A1 HK06111985.8A HK06111985A HK1091403A1 HK 1091403 A1 HK1091403 A1 HK 1091403A1 HK 06111985 A HK06111985 A HK 06111985A HK 1091403 A1 HK1091403 A1 HK 1091403A1
Authority
HK
Hong Kong
Prior art keywords
receptor subtype
subtype agonist
agonist
receptor
subtype
Prior art date
Application number
HK06111985.8A
Other languages
English (en)
Inventor
Shaun Jordan
241/352
Tetsuro Kikuchi
Katsura Tottori
Tsuyoshi Hirose
Yasufumi Uwahodo
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25087808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1091403(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of HK1091403A1 publication Critical patent/HK1091403A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK06111985.8A 2001-01-29 2006-11-01 5-ht 1a receptor subtype agonist HK1091403A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77021001A 2001-01-29 2001-01-29

Publications (1)

Publication Number Publication Date
HK1091403A1 true HK1091403A1 (en) 2007-01-19

Family

ID=25087808

Family Applications (2)

Application Number Title Priority Date Filing Date
HK04104847A HK1061805A1 (en) 2001-01-29 2004-07-06 5-Ht 1a receptor subtype agonist
HK06111985.8A HK1091403A1 (en) 2001-01-29 2006-11-01 5-ht 1a receptor subtype agonist

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK04104847A HK1061805A1 (en) 2001-01-29 2004-07-06 5-Ht 1a receptor subtype agonist

Country Status (20)

Country Link
EP (3) EP1621198B1 (xx)
JP (4) JP4178032B2 (xx)
KR (5) KR100825705B1 (xx)
CN (3) CN1239154C (xx)
AR (4) AR032641A1 (xx)
AT (3) ATE322894T1 (xx)
AU (4) AU2002226752C1 (xx)
BR (1) BR0206237A (xx)
CA (2) CA2429496C (xx)
CY (3) CY1105631T1 (xx)
DE (3) DE60239711D1 (xx)
DK (3) DK1355639T3 (xx)
ES (3) ES2286755T3 (xx)
HK (2) HK1061805A1 (xx)
MX (2) MX344556B (xx)
MY (1) MY129355A (xx)
PH (1) PH12014500937A1 (xx)
PT (3) PT1621198E (xx)
TW (2) TWI331919B (xx)
WO (1) WO2002060423A2 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
WO2004010932A2 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
EP1575590B1 (en) 2002-12-27 2007-10-24 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
KR100881046B1 (ko) 2003-05-23 2009-01-30 오쓰까 세이야꾸 가부시키가이샤 기분 장애를 치료하기 위한 카르보스티릴 유도체 및 기분안정화제
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
EP1912650B8 (en) * 2005-08-03 2017-10-18 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
TW200848041A (en) 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JP2009286740A (ja) * 2008-05-30 2009-12-10 Otsuka Pharmaceut Co Ltd アリピプラゾールを含有する逆耐性抑制剤
EP2338873A1 (en) 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
TW201343201A (zh) 2012-03-06 2013-11-01 Otsuka Pharma Co Ltd 持續釋放型口服固體製劑
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
US4764416A (en) * 1986-07-01 1988-08-16 Mitsubishi Denki Kabushiki Kaisha Electric element circuit using oxidation-reduction substances
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
ES2103374T3 (es) * 1991-05-20 1997-09-16 Upjohn Co Derivados de carboxamido-(1,2n)-carbociclo-2-aminotetralina.
US5532240A (en) * 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
AU5446894A (en) * 1992-10-23 1994-05-24 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
JP2959615B2 (ja) * 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5688950A (en) * 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
PL188164B1 (pl) * 1996-05-07 2004-12-31 Pfizer Trihydrat metanosulfonianu 5-{2-[4-1,2-benzizotiazol-3-ilo)-1-piperazynylo]etylo}-6-chloro-1,3-dihydro-2H-indol-2-onu i środek farmaceutyczny
JP4012994B2 (ja) * 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
AU4091697A (en) * 1996-08-27 1998-03-19 American Home Products Corporation 4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands
JP2002501920A (ja) * 1998-02-03 2002-01-22 アメリカン・ホーム・プロダクツ・コーポレイション セロトニン−1a受容体作動薬としてのオキサゾール誘導体
WO1999052870A1 (en) * 1998-04-13 1999-10-21 American Home Products Corporation 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
JPH11335286A (ja) * 1998-05-25 1999-12-07 Mitsui Chem Inc ドーパミン拮抗薬の効果増強剤
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
SI1627639T1 (sl) * 2001-06-19 2010-04-30 Mueller Norbert Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma

Also Published As

Publication number Publication date
EP1355639B1 (en) 2006-04-12
MX344556B (es) 2016-12-20
WO2002060423A2 (en) 2002-08-08
DE60210581T2 (de) 2007-04-05
CN1239154C (zh) 2006-02-01
AU2002226752C1 (en) 2010-02-18
KR100763288B1 (ko) 2007-10-04
EP1712225B1 (en) 2011-04-06
PT1621198E (pt) 2007-06-08
CY1105631T1 (el) 2010-12-22
KR20070065425A (ko) 2007-06-22
MY129355A (en) 2007-03-30
KR20060085260A (ko) 2006-07-26
JP5683010B2 (ja) 2015-03-11
AU2002226752B2 (en) 2005-03-17
CN1484524A (zh) 2004-03-24
TWI302832B (en) 2008-11-11
AU2009233591A1 (en) 2009-11-19
CN100450485C (zh) 2009-01-14
KR20030065570A (ko) 2003-08-06
AR079761A2 (es) 2012-02-15
AU2009233591B2 (en) 2011-10-20
ES2286755T3 (es) 2007-12-01
EP1355639A2 (en) 2003-10-29
CA2700314C (en) 2012-04-24
CA2429496C (en) 2010-10-19
DE60210581D1 (en) 2006-05-24
AU2007201701A1 (en) 2007-05-10
CY1111392T1 (el) 2015-08-05
DK1621198T3 (da) 2007-09-24
KR20060028485A (ko) 2006-03-29
AR080849A2 (es) 2012-05-09
EP1621198B1 (en) 2007-05-23
JP2007297405A (ja) 2007-11-15
KR20050107822A (ko) 2005-11-15
KR100825705B1 (ko) 2008-04-29
AU2007201701B2 (en) 2010-06-17
DE60220325T2 (de) 2008-01-17
JP2011225587A (ja) 2011-11-10
JP2004517937A (ja) 2004-06-17
JP2011184460A (ja) 2011-09-22
KR100653591B1 (ko) 2006-12-05
PT1712225E (pt) 2011-04-18
EP1621198A3 (en) 2006-04-12
CN1813745A (zh) 2006-08-09
WO2002060423A3 (en) 2003-04-10
CA2429496A1 (en) 2002-08-08
TWI331919B (en) 2010-10-21
JP4178032B2 (ja) 2008-11-12
CN1879624A (zh) 2006-12-20
DE60220325D1 (de) 2007-07-05
ATE322894T1 (de) 2006-04-15
PH12014500937A1 (en) 2015-09-21
AR032641A1 (es) 2003-11-19
EP1712225A1 (en) 2006-10-18
KR100601073B1 (ko) 2006-07-19
ES2261652T3 (es) 2006-11-16
DK1712225T3 (da) 2011-06-20
BR0206237A (pt) 2003-12-23
CY1108031T1 (el) 2013-09-04
PT1355639E (pt) 2006-06-30
DE60239711D1 (de) 2011-05-19
DK1355639T3 (da) 2006-08-14
HK1061805A1 (en) 2004-10-08
ATE504293T1 (de) 2011-04-15
AR099754A2 (es) 2016-08-17
AU2005201772B2 (en) 2007-05-17
JP4896831B2 (ja) 2012-03-14
EP1621198A2 (en) 2006-02-01
AU2005201772C1 (en) 2010-06-03
CA2700314A1 (en) 2002-08-08
MXPA03006603A (es) 2004-02-12
TW200522960A (en) 2005-07-16
AU2005201772A1 (en) 2005-05-19
KR100713607B1 (ko) 2007-05-02
ATE362763T1 (de) 2007-06-15
ES2363366T3 (es) 2011-08-02

Similar Documents

Publication Publication Date Title
HK1091403A1 (en) 5-ht 1a receptor subtype agonist
AUPR833401A0 (en) G protein-coupled receptor antagonists
AU2002367424A1 (en) Androgen receptor antagonists
IL158807A0 (en) 5-ht receptor ligands and uses thereof
AU1211802A (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
EP1351933A4 (en) ANTAGONISTS OF IL-8 RECEPTORS
IL153837A0 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
AU2002351730A1 (en) Glucagon receptor antagonists/inverse agonists
PL370799A1 (en) Aminotetralin derivatives as muscarinic receptor antagonists
AU2001245724A1 (en) Il-8 receptor antagonists
AU2001240021A1 (en) Diazafluorenone il-8 receptor antagonists
AU2001243351A1 (en) Il-8 receptor antagonists
GB0203412D0 (en) 5-HT 2B receptor antagonists
AU1100300A (en) Piperidyloxadiazoles as dopamine receptor antagonists
AU2001241896A1 (en) Il-8 receptor antagonists
AU2001253172A1 (en) Il-8 receptor antagonists
IL144810A0 (en) Dopamine d1 receptor agonist compounds
AU2001245605A1 (en) Il-8 receptor antagonists
AU2002302774A1 (en) Macrophage receptor agonist or antagonist
IL158063A0 (en) Crf receptor antagonists
GB0203413D0 (en) 5-HT 2B receptor antagonists
AU2002258506A1 (en) Dopamine d4 receptor antagonists as treatment for attention deficit-hyperactivity disorder
AU2002338040A1 (en) Receptor antagonist
GB0110662D0 (en) Receptor
GB0125183D0 (en) Receptor

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220128